Gong 2023 Biomed Pharmacother: Difference between revisions
(Created page with "{{Publication |title=Gong DF, Sun SC, Wang RR, Dawuti A, Kong DW, Liu RQ, Du LD, Wang SB, Lu Y, Yuan TY, Du GH, Fang LH (2023) Salvianolic acid A improve mitochondrial respira...") |
No edit summary |
||
| Line 6: | Line 6: | ||
|journal=Biomed Pharmacother | |journal=Biomed Pharmacother | ||
|abstract=Salvianolic acid A (SAA) is a traditional Chinese medicine that has a good therapeutic effect on cardiovascular disease. However, the underlying mechanisms by which SAA improves mitochondrial respiration and cardiac function in diabetic cardiomyopathy (DCM) remain unknown. This study aims to elucidate whether SAA had any cardiovascular protection on the pathophysiology of DCM and explored the potential mechanisms. Diabetes was induced in rats by 30 mg/kg of streptozotocin (STZ) treatment. After a week of stability, 5 mg/kg isoprenaline (ISO) was injected into the rats subcutaneously. 3 mg/kg SAA was orally administered for six weeks and 150 mg/kg Metformin was selected as a positive group. At the end of this period, cardiac function was assessed by ultrasound, electrocardiogram, and relevant cardiac injury biomarkers testing. Treatment with SAA improved cardiac function, glucose, and lipid levels, mitochondrial respiration, and suppressed myocardial inflammation and apoptosis. Furthermore, SAA treatment inhibits the apoptosis pathway through CRYAB in diabetic cardiomyopathy rats. As a result, this study not only provides new insights into the mechanism of SAA against DCM but also provides new therapeutic ideas for the discovery of anti-DCM compounds in the clinic. | |abstract=Salvianolic acid A (SAA) is a traditional Chinese medicine that has a good therapeutic effect on cardiovascular disease. However, the underlying mechanisms by which SAA improves mitochondrial respiration and cardiac function in diabetic cardiomyopathy (DCM) remain unknown. This study aims to elucidate whether SAA had any cardiovascular protection on the pathophysiology of DCM and explored the potential mechanisms. Diabetes was induced in rats by 30 mg/kg of streptozotocin (STZ) treatment. After a week of stability, 5 mg/kg isoprenaline (ISO) was injected into the rats subcutaneously. 3 mg/kg SAA was orally administered for six weeks and 150 mg/kg Metformin was selected as a positive group. At the end of this period, cardiac function was assessed by ultrasound, electrocardiogram, and relevant cardiac injury biomarkers testing. Treatment with SAA improved cardiac function, glucose, and lipid levels, mitochondrial respiration, and suppressed myocardial inflammation and apoptosis. Furthermore, SAA treatment inhibits the apoptosis pathway through CRYAB in diabetic cardiomyopathy rats. As a result, this study not only provides new insights into the mechanism of SAA against DCM but also provides new therapeutic ideas for the discovery of anti-DCM compounds in the clinic. | ||
|keywords=Apoptosis, CRYAB, Diabetic cardiomyopathy, Mitochondrial, Salvianolic acid A | |||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
}} | }} | ||
Revision as of 17:32, 20 February 2023
| Gong DF, Sun SC, Wang RR, Dawuti A, Kong DW, Liu RQ, Du LD, Wang SB, Lu Y, Yuan TY, Du GH, Fang LH (2023) Salvianolic acid A improve mitochondrial respiration and cardiac function via inhibiting apoptosis pathway through CRYAB in diabetic cardiomyopathy. https://doi.org/10.1016/j.biopha.2023.114382 |
» Biomed Pharmacother 160:114382. PMID: 36773525 Open Access
Gong DF, Sun SC, Wang RR, Dawuti A, Kong DW, Liu RQ, Du LD, Wang SB, Lu Y, Yuan TY, Du GH, Fang LH (2023) Biomed Pharmacother
Abstract: Salvianolic acid A (SAA) is a traditional Chinese medicine that has a good therapeutic effect on cardiovascular disease. However, the underlying mechanisms by which SAA improves mitochondrial respiration and cardiac function in diabetic cardiomyopathy (DCM) remain unknown. This study aims to elucidate whether SAA had any cardiovascular protection on the pathophysiology of DCM and explored the potential mechanisms. Diabetes was induced in rats by 30 mg/kg of streptozotocin (STZ) treatment. After a week of stability, 5 mg/kg isoprenaline (ISO) was injected into the rats subcutaneously. 3 mg/kg SAA was orally administered for six weeks and 150 mg/kg Metformin was selected as a positive group. At the end of this period, cardiac function was assessed by ultrasound, electrocardiogram, and relevant cardiac injury biomarkers testing. Treatment with SAA improved cardiac function, glucose, and lipid levels, mitochondrial respiration, and suppressed myocardial inflammation and apoptosis. Furthermore, SAA treatment inhibits the apoptosis pathway through CRYAB in diabetic cardiomyopathy rats. As a result, this study not only provides new insights into the mechanism of SAA against DCM but also provides new therapeutic ideas for the discovery of anti-DCM compounds in the clinic. • Keywords: Apoptosis, CRYAB, Diabetic cardiomyopathy, Mitochondrial, Salvianolic acid A • Bioblast editor: Plangger M
Labels: MiParea: Respiration
HRR: Oxygraph-2k
2023-02
